Table 1 Clinical data of SpA patients, according to EMMs used for driving the therapeutic decision-making at baseline
Variable | rAAU (N = 48) | Psoriasis (N = 78) | IBD (N = 15) | p |
|---|---|---|---|---|
Male, n (%) | 29 (60.4%) | 48 (61.5%) | 7 (46.7%) | 0.55 |
Age (Years) | 49.1 (12.1) | 57.8 (14.5) | 47.9 (14.8) | 0.001 |
Skin color | ||||
 White, n (%) | 27 (56.3%) | 51 (65.4%) | 10 (66.7%) | 0.46 |
 Non-white, n (%) | 21 (43.7%) | 24 (30.8%) | 5 (33.3%) | |
 Unknown, n (%) | 0 | 3 (3.8%) | 0 | |
Time of disease (years) | 18.7 (9.6) | 22.6 ( | 13 (8.1) | 0.01 |
Family History of SpA, n (%) | 11 (22.9%) | 12 (15.4%) | 1 (6.7%) | 0.29 |
DAIAGNOSTIC DELAY (years) | 11.8 (9.4) | 15.9 (12.4) | 5.7 (5.9) | 0.001 |
Current smoking, n (%) | 4 (8.3%) | 13 (16.7%) | 1 (6.7%) | 0.3 |
Positivity for HLA-B27, n (%) | 33 (68.8%) | 5 (6.4%) | 5 (33.3%) |  < 0.0001 |
Axial predominance, n (%) | 15 (31.2%) | 1 (1.3%) | 3 (20%) |  < 0.0001 |
Peripheral predominance, n (%) | 1 (2.1%) | 28 (35.9%) | 2 (13.3%) |  < 0.0001 |
Comorbidities Fibromyalgia, n (%) | 6 (12.5%) | 7 (9%) | 2 (13.3%) | 0.77 |
Low BMD for age, n (%) | 10 (20.8%) | 18 (23.1%) | 6 (40%) | 0.30 |